$ACHV
ACHIEVE LIFE SCIENCES, INC.

2017 Q4 Form 10-Q Financial Statement

#000156459017023285 Filed on November 09, 2017

View on sec.gov

Income Statement

Concept 2017 Q4 2017 Q3 2016 Q4
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.630M $1.550M $2.300M
YoY Change -29.13% -16.67% -21.23%
% of Gross Profit
Research & Development $2.153M $825.0K $80.00K
YoY Change 2591.25% 1095.65% -98.79%
% of Gross Profit
Depreciation & Amortization $90.00K $60.00K $40.00K
YoY Change 125.0% 20.0% -33.33%
% of Gross Profit
Operating Expenses $2.153M $825.0K $80.00K
YoY Change 2591.25% 1095.65% -98.79%
Operating Profit
YoY Change
Interest Expense $10.00K $10.00K $40.00K
YoY Change -75.0% -80.0% 33.33%
% of Operating Profit
Other Income/Expense, Net $42.00K -$7.025M -$4.000K
YoY Change -1150.0% 100257.14% -100.23%
Pretax Income -$3.740M -$9.400M -$5.840M
YoY Change -35.96% 2220.99% 239.53%
Income Tax $0.00 -$2.930M
% Of Pretax Income
Net Earnings -$3.740M -$6.469M -$486.0K
YoY Change 669.55% 2313.81% -71.78%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$62.33M -$161.8M -$584.0M
COMMON SHARES
Basic Shares Outstanding 11.95M 30.02M
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q4 2017 Q3 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.300M $8.000M $10.25M
YoY Change -48.27% -37.41% -51.08%
Cash & Equivalents $5.284M $8.021M $15.00K
Short-Term Investments $10.23M
Other Short-Term Assets $600.0K $500.0K $1.000M
YoY Change -40.0% -72.22% 7042.86%
Inventory
Prepaid Expenses $393.0K $535.0K $3.000K
Receivables $0.00 $70.00K $478.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $5.900M $8.626M $18.00K
YoY Change 32677.78% -74.85% -99.97%
LONG-TERM ASSETS
Property, Plant & Equipment $100.0K $94.00K $300.0K
YoY Change -66.67% -81.2% -50.0%
Goodwill $1.034M $1.034M $1.034M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $400.0K $415.0K $300.0K
YoY Change 33.33% 38.33% 0.0%
Total Long-Term Assets $3.992M $4.403M $3.789M
YoY Change 5.36% 450.38% 320.07%
TOTAL ASSETS
Total Short-Term Assets $5.900M $8.626M $18.00K
Total Long-Term Assets $3.992M $4.403M $3.789M
Total Assets $9.892M $13.03M $3.807M
YoY Change 159.84% -62.88% -93.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $213.0K $495.0K $95.00K
YoY Change 124.21% -50.5% -92.69%
Accrued Expenses $1.800M $1.800M $6.000M
YoY Change -70.0% -80.22% -49.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $100.0K
YoY Change -100.0% -100.0% 0.0%
Total Short-Term Liabilities $2.013M $2.331M $3.073M
YoY Change -34.49% -77.98% -85.13%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.013M $2.331M $3.073M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.013M $2.347M $3.197M
YoY Change -37.03% -77.97% -84.61%
SHAREHOLDERS EQUITY
Retained Earnings -$12.69M -$8.915M -$2.062M
YoY Change 515.62% -95.33% -98.83%
Common Stock $20.57M $19.59M $2.696M
YoY Change 662.91% -90.8% -98.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.80M $10.68M $610.0K
YoY Change
Total Liabilities & Shareholders Equity $9.892M $13.03M $3.807M
YoY Change 159.84% -62.85% -93.46%

Cashflow Statement

Concept 2017 Q4 2017 Q3 2016 Q4
OPERATING ACTIVITIES
Net Income -$3.740M -$6.469M -$486.0K
YoY Change 669.55% 2313.81% -71.78%
Depreciation, Depletion And Amortization $90.00K $60.00K $40.00K
YoY Change 125.0% 20.0% -33.33%
Cash From Operating Activities -$3.630M $6.050M -$6.980M
YoY Change -47.99% -183.33% -34.64%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K
YoY Change -85.71%
Acquisitions
YoY Change
Other Investing Activities $270.0K $2.150M $10.42M
YoY Change -97.41% -74.65% 305.45%
Cash From Investing Activities $270.0K $2.150M $10.42M
YoY Change -97.41% -74.65% 316.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 890.0K 1.130M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -3.630M 6.050M -6.980M
Cash From Investing Activities 270.0K 2.150M 10.42M
Cash From Financing Activities 890.0K 1.130M 0.000
Net Change In Cash -2.470M 9.330M 3.440M
YoY Change -171.8% 664.75% -142.11%
FREE CASH FLOW
Cash From Operating Activities -$3.630M $6.050M -$6.980M
Capital Expenditures -$10.00K
Free Cash Flow -$6.970M
YoY Change -34.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7000
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7000
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7000
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7025000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1902000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
899000
CY2017Q3 us-gaap Costs And Expenses
CostsAndExpenses
2375000
dei Trading Symbol
TradingSymbol
ACHV
dei Entity Registrant Name
EntityRegistrantName
ACHIEVE LIFE SCIENCES, INC.
CY2017Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11947676
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8021000
dei Entity Central Index Key
EntityCentralIndexKey
0000949858
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15000
us-gaap Net Income Loss
NetIncomeLoss
-748000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
206000
us-gaap Costs And Expenses
CostsAndExpenses
2850000
CY2016Q3 us-gaap Costs And Expenses
CostsAndExpenses
398000
us-gaap Costs And Expenses
CostsAndExpenses
1105000
CY2017Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
9000
CY2017Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
70000
CY2017Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
535000
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3000
CY2017Q3 us-gaap Assets Current
AssetsCurrent
8626000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
18000
CY2017Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
272000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000
CY2017Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
223000
CY2017Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
223000
CY2017Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
223000
us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
3548
us-gaap Net Income Loss
NetIncomeLoss
-6843000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-111000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2667000
CY2017Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8915000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2062000
CY2017Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
94000
CY2017Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
415000
CY2017Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2588000
CY2016Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2755000
CY2017Q3 us-gaap Goodwill
Goodwill
1034000
CY2016Q4 us-gaap Goodwill
Goodwill
1034000
CY2017Q3 us-gaap Assets
Assets
13029000
CY2016Q4 us-gaap Assets
Assets
3807000
CY2017Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
495000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
95000
CY2017Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1297000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1121000
CY2017Q3 achv Accrued Liabilities Clinical Current
AccruedLiabilitiesClinicalCurrent
162000
CY2017Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
343000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1028000
CY2016Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
829000
CY2017Q3 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
31000
CY2017Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
3000
CY2017Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2331000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3073000
CY2017Q3 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
16000
CY2016Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
124000
CY2017Q3 us-gaap Liabilities
Liabilities
2347000
CY2016Q4 us-gaap Liabilities
Liabilities
3197000
CY2017Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q3 us-gaap Common Stock Value
CommonStockValue
11000
CY2017Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
19581000
CY2017Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5000
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
10682000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
610000
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13029000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3807000
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11491665
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21230
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11482845
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21230
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
825000
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
69000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
948000
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1550000
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
329000
us-gaap Investment Income Interest
InvestmentIncomeInterest
9000
CY2017Q3 us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
1272000
us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
1272000
CY2017Q3 achv Contingent Value Rights Recovery
ContingentValueRightsRecovery
200000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-4000
achv Contingent Value Rights Recovery
ContingentValueRightsRecovery
200000
CY2017Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-111000
CY2017Q3 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
-8610000
us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
-8610000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-26000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-20000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7044000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-20000
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9400000
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-405000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9894000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1125000
CY2017Q3 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2928000
CY2016Q3 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-137000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-3051000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-377000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-6472000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-268000
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6472000
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-268000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6843000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-748000
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.90
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-12.62
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.81
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-35.23
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7225826
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21230
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2435095
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21230
us-gaap Depreciation And Amortization
DepreciationAndAmortization
191000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
166000
us-gaap Share Based Compensation
ShareBasedCompensation
152000
achv Contingent Value Rights Liability Recovery
ContingentValueRightsLiabilityRecovery
200000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
164000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1597000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
400000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
48000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1123000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
299000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
162000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-685000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
471000
achv Increase Decrease In Lease Obligations
IncreaseDecreaseInLeaseObligations
-47000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5484000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-140000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
100000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
1129000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
22000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1107000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
100000
achv Cash Assumed In Reverse Merger
CashAssumedInReverseMerger
12376000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
12376000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
7000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
8006000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-40000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
67000
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27000
CY2017Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
3000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
114000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
111000
us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
0
achv Share Based Compensation Arrangement By Share Based Payment Award Options Additions On Reverse Takeover
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionsOnReverseTakeover
113451
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1052200
CY2017Q3 us-gaap Cash
Cash
3010000
achv Maximum Maturity Period Of Cash And Cash Equivalents
MaximumMaturityPeriodOfCashAndCashEquivalents
P90D
achv Maximum Maturity Period Of Short Term Investments
MaximumMaturityPeriodOfShortTermInvestments
P1Y
CY2017Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2017Q3 achv Working Capital Balance
WorkingCapitalBalance
6300000
CY2017Q3 us-gaap Finite Lived Intangible Assets Fair Value Disclosure
FiniteLivedIntangibleAssetsFairValueDisclosure
8600000
CY2017Q3 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P6Y
CY2015Q2 us-gaap Finite Lived Intangible Assets Fair Value Disclosure
FiniteLivedIntangibleAssetsFairValueDisclosure
3100000
CY2015Q2 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P14Y
CY2017Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000
CY2016Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100000
CY2017Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
56000
CY2017Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
223000
CY2017Q3 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
1640000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
19544
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1146107
achv Share Based Compensation Arrangements By Share Based Payment Award Options Additions On Reverse Takeover In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAdditionsOnReverseTakeoverInPeriodWeightedAverageExercisePrice
92.61
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.89
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
114.53
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.87
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0195
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8606
CY2017Q3 us-gaap Share Based Compensation
ShareBasedCompensation
152000
CY2017Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2100000
CY2016Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
0
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1700000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1700000
CY2016Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0
achv Number Of Warrants Exercised
NumberOfWarrantsExercised
0
achv Number Of Warrants Exercised
NumberOfWarrantsExercised
0
CY2017Q3 us-gaap Contractual Obligation
ContractualObligation
278000
CY2017Q3 us-gaap Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year
ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear
278000
achv Expiration Of Operating Lease Agreement
ExpirationOfOperatingLeaseAgreement
2018-09
CY2017Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
100000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
100000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
0
CY2017Q3 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
achv Indemnification Expense
IndemnificationExpense
0
CY2017Q3 achv Number Of Terminated Senior Executives
NumberOfTerminatedSeniorExecutives
1

Files In Submission

Name View Source Status
0001564590-17-023285-index-headers.html Edgar Link pending
0001564590-17-023285-index.html Edgar Link pending
0001564590-17-023285.txt Edgar Link pending
0001564590-17-023285-xbrl.zip Edgar Link pending
achv-10q_20170930.htm Edgar Link pending
achv-20170930.xml Edgar Link completed
achv-20170930.xsd Edgar Link pending
achv-20170930_cal.xml Edgar Link unprocessable
achv-20170930_def.xml Edgar Link unprocessable
achv-20170930_lab.xml Edgar Link unprocessable
achv-20170930_pre.xml Edgar Link unprocessable
achv-ex101_1096.htm Edgar Link pending
achv-ex311_9.htm Edgar Link pending
achv-ex312_7.htm Edgar Link pending
achv-ex321_6.htm Edgar Link pending
achv-ex322_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending